Guardant Health to ring Nasdaq opening bell on August 28 to celebrate launch of Shield colorectal cancer screening blood test

Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, today announced that the Company will ring the opening bell on Wednesday, August 28, 2024 at the Nasdaq MarketSite in Times Square, New York.

“We recently launched Shield, our FDA-cleared blood test, which marks a pivotal moment in our journey to defeat cancer with data. We are excited to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after we first rang the bell for our IPO,” said AmirAli Talasaz, co-CEO of Guardant Health. “Shield provides a more convenient way to stay up-to-date on colorectal cancer screening and detect the disease early, when patients have the best chance of survival. This launch is a historic moment for Guardant, the field of liquid biopsy, cancer screening, and most importantly, for patients. I want to thank our team for their hard work over the past 10 years to get us here.”